Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Martin Ritter

Bernd Kuhn

Hans G Richter

Fionn O'Hara

Buelent Kocer

Uwe Grether

Benoit Hornsperger

Joerg Benz

Carsten Kroll

Bernd Buettelmann

Luca Claudio Gobbi

Katrin Groebke Zbinden

Marco Prunotto

Rainer Eugen Martin

Markus Rudolph

Didier Rombach

Bernd Puellmann

Alexander Lee Satz

Martin Kuratli

Hans Richter

Satoshi Tsuchiya

Dennis Jul Hansen

Philipp Schmid

Charles Bell

Marius Daniel Rinaldo Lutz

Simon E Johnson

Rui Chen

Ludovic Collin

Fionn O`hara

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Heterocyclic compounds as monoacylglycerol lipase inhibitors

The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, Rand Rto Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Heterocyclic compounds

The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, m, n, and Rto Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, 

Piperazine derivatives as MAGL inhibitors

The present invention relates to compounds of formula (I): 

Spiroindolinones as DDR1 inhibitors

Triaza-spirodecanones as DDR1 inhibitors

Growing community of inventors

Basel, Switzerland

Martin Ritter